What is the official website of Sandoz Iberia ?

The official website of Sandoz Iberia is https://sandozfarma.es/.

What is Sandoz Iberia's cybersecurity risk score?

Sandoz Iberia has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Sandoz Iberia experienced?

According to Rankiteo, Sandoz Iberia currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Sandoz Iberia been affected by any supply chain cyber incidents ?

According to Rankiteo, Sandoz Iberia has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Sandoz Iberia have SOC 2 Type 1 certification ?

According to Rankiteo, Sandoz Iberia is not certified under SOC 2 Type 1.

Does Sandoz Iberia have SOC 2 Type 2 certification ?

According to Rankiteo, Sandoz Iberia does not hold a SOC 2 Type 2 certification.

Does Sandoz Iberia comply with GDPR ?

According to Rankiteo, Sandoz Iberia is not listed as GDPR compliant.

Does Sandoz Iberia have PCI DSS certification ?

According to Rankiteo, Sandoz Iberia does not currently maintain PCI DSS compliance.

Does Sandoz Iberia comply with HIPAA ?

According to Rankiteo, Sandoz Iberia is not compliant with HIPAA regulations.

Does Sandoz Iberia have ISO 27001 certification ?

According to Rankiteo,Sandoz Iberia is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Sandoz Iberia operate in ?

Sandoz Iberia operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Sandoz Iberia have ?

Sandoz Iberia employs approximately 122 people worldwide.

Does Sandoz Iberia own any subsidiaries ?

Sandoz Iberia presently has no subsidiaries across any sectors.

How many LinkedIn followers does Sandoz Iberia have ?

Sandoz Iberia's official LinkedIn profile has approximately 19,172 followers.

What is the NAICS classification code for Sandoz Iberia ?

Sandoz Iberia is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Sandoz Iberia have a Crunchbase profile ?

No, Sandoz Iberia does not have a profile on Crunchbase.

Does Sandoz Iberia have a LinkedIn profile ?

Yes, Sandoz Iberia maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/sandoziberia.

How many cybersecurity incidents has Sandoz Iberia experienced ?

As of July 29, 2026, Rankiteo reports that Sandoz Iberia has not experienced any cybersecurity incidents.

How many peer or competitor companies does Sandoz Iberia have ?

Sandoz Iberia has an estimated 5,712 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Sandoz Iberia

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Sandoz Iberia Vendor Cyber Rating & Cyber Score

sandozfarma.es

Add Your Compliance Badge

En Sandoz, nuestro propósito es ser pioneros en facilitar el acceso a la salud de los pacientes y aspiramos a ser la empresa de genéricos y biosimilares líder y más valorada del mundo. El origen de la compañía se remonta a Basilea, Suiza, en 1886. Nos enorgullecemos de nuestra larga trayectoria, que hoy es sinónimo de calidad, fiabilidad e innovación. Más de 20.000 personas de 100 nacionalidades trabajamos juntas para garantizar que Sandoz proporcione 900 millones de tratamientos a pacientes anuales, lo que genera un ahorro sanitario y un impacto social aún mayor. Somos el número 1 en el mercado mundial de genéricos si se comparan las ventas netas, el segundo en biosimilares y la empresa de genéricos líder en Europa. Estamos trabajando

Sandoz Iberia A.I CyberSecurity Scoring

Scoring History

Sandoz Iberia

Sandoz Iberia CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Sandoz Iberia Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Sandoz Iberia

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Sandoz Iberia in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Sandoz Iberia in 2026.

Incident Types Sandoz Iberia vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Sandoz Iberia in 2026.

Incident History - Sandoz Iberia (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Sandoz Iberia Subsidiaries

Sandoz Iberia

Pharmaceutical Manufacturing

Website: https://sandozfarma.es/

Company Size: 501-1,000 employees

SandozPharmaceutical Manufacturing

Sandoz ItaliaPharmaceutical Manufacturing

Sandoz RomaniaPharmaceutical Manufacturing

Sandoz BelgiumPharmaceutical Manufacturing

Sandoz CanadaPharmaceutical Manufacturing

Sandoz do BrasilFabricação de produtos farmoquímicos e farmacêuticos

Lek PharmaceuticalsPharmaceutical Manufacturing

Sandoz FrancePharmaceutical Manufacturing

Sandoz PolskaPharmaceutical Manufacturing

Sandoz EgyptPharmaceutical Manufacturing

Sandoz in DeutschlandPharmaceutical Manufacturing

Sandoz Czech RepublicPharmaceutical Manufacturing

Sandoz India Pvt LtdPharmaceutical Manufacturing

Sandoz HrvatskaPharmaceutical Manufacturing

Life at SandozArzneimittelherstellung

Sandoz UK & IrelandPharmaceutical Manufacturing

Sandoz SrbijaPharmaceutical Manufacturing

Sandoz HungáriaPharmaceutical Manufacturing

Sandoz ÖsterreichPharmaceutical Manufacturing

Sandoz SverigePharmaceutical Manufacturing

Sandoz MéxicoPharmaceutical Manufacturing

Sandoz Australia & New ZealandPharmaceutical Manufacturing

Sandoz DanmarkPharmaceutical Manufacturing

Sandoz NederlandPharmaceutical Manufacturing

Loading…

Sandoz Iberia Similar Companies

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Loading…

NEWS

Sandoz Iberia CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-66064

SUMMARY

goshs is a feature-rich single-binary file server for red teamers and developers. Prior to 2.1.5, the httpserver/handler.go sendFile handler opened files using a cleaned path but derived the authorization filename from raw req.URL.Path, so a trailing slash could bypass .goshs ACL-file protection and block-list checks. This issue is fixed in version 2.1.5.

Published

Date2026-07-28

Updated

Date2026-07-28

RISK INFORMATION (Score: 5.3)

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-66063

SUMMARY

goshs is a feature-rich single-binary file server for red teamers and developers. Prior to 2.1.5, the httpserver/updown.go multipart upload handler split part.FileName() on / but did not reject .., allowing an unauthenticated upload with filename .. to create a file outside the served tree. This issue is fixed in version 2.1.5.

Published

Date2026-07-28

Updated

Date2026-07-28

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:N

Impact Score

2.5

Exploitability

3.9

REFERENCES

CVE-2026-64863

SUMMARY

goshs is a feature-rich single-binary file server for red teamers and developers. Prior to 2.1.4, the httpserver/server.go wdGuard handled WebDAV MOVE as a write-only method and did not enforce --no-delete, allowing WebDAV clients to delete or overwrite files via MOVE with Overwrite: T. This issue is fixed in version 2.1.4.

Published

Date2026-07-28

Updated

Date2026-07-28

RISK INFORMATION (Score: 9.1)

cvss3

Base Score: 9.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:H/A:H

Impact Score

5.2

Exploitability

3.9

REFERENCES

CVE-2026-62325

SUMMARY

goshs is a feature-rich single-binary file server for red teamers and developers. From 2.1.3 until 2.1.4, the sftpserver/sftpserver.go password handler used Username != "" && Password != "", so running goshs with -b 'admin:' -sftp and no -fkf left both SFTP authentication handlers unset and allowed unauthenticated file access. This issue is fixed in version 2.1.4.

Published

Date2026-07-28

Updated

Date2026-07-28

RISK INFORMATION (Score: 9.1)

cvss3

Base Score: 9.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N

Impact Score

5.2

Exploitability

3.9

REFERENCES

CVE-2026-59921

SUMMARY

Netty is an asynchronous, event-driven network application framework. Prior to versions 4.1.136.Final and 4.2.16.Final, HttpPostRequestEncoder constructs multipart HTTP request bodies by directly concatenating user-supplied filenames and field names into Content-Disposition MIME headers without validating or sanitizing CRLF characters (\r\n). Since MIME headers are delimited by CRLF, an attacker who controls the filename can inject arbitrary MIME headers into the multipart body part. The root cause is that neither the encoder nor the FileUpload implementations' setFilename() methods, which only check for null, neutralize CRLF characters before the filename is embedded into the header. This issue has been fixed in versions 4.1.136.Final and 4.2.16.Final.

Published

Date2026-07-28

Updated

Date2026-07-28

RISK INFORMATION (Score: 5.7)

cvss3

Base Score: 5.7

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:L/UI:N/S:U/C:N/I:H/A:N

Impact Score

3.6

Exploitability

2.1

REFERENCES

https://github.com/netty/netty/security/advisories/GHSA-gcjf-9mgh-3p7g

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…